Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about AMGEN
10/16 AMGEN : And Boston Children's Hospital Enter A Collaboration To Find New Genes A..
10/12 AMGEN : Foundation Awards Khan Academy $3 Million To Support Development Of Free..
10/12 AMGEN : FDA Accepts Supplemental Biologics License Application for Prolia in Glu..
10/10 HERE’S WHAT’S MOVING ONC : ONTX) and Amgen (NASDAQ:AMGN)
10/10 AMGEN : First Randomized Study to Evaluate IMLYGIC an Oncolytic Viral Therapy
10/10 MACKENZIE CORE PLUS GLOBAL : Immatics Receives $58 Million in Financing to Devel..
10/10 AMGEN : FDA Accepts SBLA For Prolia
10/09 AMGEN : FDA Accepts Supplemental Biologics License Application For Prolia® (Deno..
10/06 AMGEN : And LabCentral Open Nomination Process For Lab Residency
10/06 AMGEN : and CytomX Therapeutics Announce Strategic Collaboration in Immuno Oncol..
10/05 AMGEN : First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), ..
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
10/02 AMGEN : Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, Ne..
10/02 AMGEN : And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA
More most relevant news
All news about AMGEN
10/16 AMGEN : And Boston Children's Hospital Enter A Collaboration To Find New Genes A..
10/12 AMGEN : Wins Reprieve on Its 2nd-Best-Selling Drug
10/12 AMGEN : Reports on Biosimilars from Amgen Provide New Insights (A phase I, rando..
10/12 Loncar Cancer Immunotherapy Index Announces Merger Replacements
10/12 AMGEN : Foundation Awards Khan Academy $3 Million To Support Development Of Free..
10/12 AMGEN : FDA Accepts Supplemental Biologics License Application for Prolia in Glu..
10/11 BIOCON : Mylan and Biocon biosimilar of Amgens Neulasta hit with manufacturing-r..
10/10 HERE’S WHAT’S MOVING ONC : ONTX) and Amgen (NASDAQ:AMGN)
10/10 AMGEN : First Randomized Study to Evaluate IMLYGIC an Oncolytic Viral Therapy
10/10 MACKENZIE CORE PLUS GLOBAL : Immatics Receives $58 Million in Financing to Devel..
More news
Sector news : Pharmaceuticals - NEC
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 Miners provide foundation for FTSE while ConvaTec plummets
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 CONVATEC : slashes revenue growth outlook, shares slump
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/16 Amgen teams up with Boston Children's Hospital to identify new pain targets
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
10/16 President Trump at it again with comments on "out of control" drug prices
10/15 DIVIDEND INCOME UPDATE : September 2017
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/11 YOUR DAILY PHARMA SCOOP : Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosu..
Latest Tweets
03:45aAmgen And Boston Children's Hospital Enter A Collaboration To Find New Genes .. 
12:02a$AMGN: Amgen and the Boston Children's hospital have entered into a neuroscie.. 
10/16Amgen teams up with Boston Children's Hospital to identify new pain targets  
10/16BRIEF-Amgen and Boston Children's Hospital enter into neuroscience research c.. 
10/16Today #Amgen & @BostonChildrens announce collaboration to validate geneti..
3
More tweets
Qtime:281
Financials ($)
Sales 2017 22 854 M
EBIT 2017 11 807 M
Net income 2017 8 130 M
Finance 2017 4 380 M
Yield 2017 2,47%
P/E ratio 2017 16,43
P/E ratio 2018 16,08
EV / Sales 2017 5,62x
EV / Sales 2018 5,48x
Capitalization 133 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 190 $
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN25.17%132 728
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887